On July 16-20, the Alzheimer’s Association will hold its annual Alzheimer’s Association International Conference (AAIC), in London, which is led by the world’s leading researchers, investigators, and clinicians, joining forces to share the latest research in dementia.1
Alzheimer's disease is the most common form of dementia worldwide and is a major health challenge facing the world today.2,3 With our partner, Eli Lilly and Company, we are proud to be playing a meaningful role in the development of potential treatments for this disease.
The progression of Alzheimer’s disease is characterised by the accumulation of amyloid plaque in the brain, which is comprised of peptides called amyloid beta.2 Additionally, beta-secretase cleaving enzyme is an enzyme associated with the development of amyloid beta, a molecule that, when produced in excess, clumps together to form the damaging plaques.2,3
We remain committed to exploring and seeking a solution to end Alzheimer’s disease by following the science and putting patients first.
We appreciate the fact that a treatment for Alzheimer’s disease is one of the largest unmet needs we face in medical science today. Alzheimer’s is a particularly cruel disease for both patients and their caregivers. In partnership with Eli Lilly and Company, we will strive to bring scientific and executional strength to tackle the challenge of Alzheimer’s disease for patients and their caregivers.
1. Alzheimer’s Association. About AAIC. https://www.alz.org/aaic/about/overview.asp. Accessed June 2017.
2. O’Brien, R, et al. Amyloid Precursor Protein Processing and Alzheimer’s Disease. Annu Rev Neurosci. 2011 ; 34: 185–204.
3. Menting KW, et al. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease. Front. Aging Neurosci. 6:165. doi:10.3389/fnagi.2014.00165.